World Vaccine Partnering Congress Asia Day Two - 13 June 2012

last modified: 24 May '12

Please enable javascript to see more information on speakers

08.30
Registration and refreshments
08.50
Chairman’s opening remarks

STRATEGIES FOR THE ASIAN VACCINE MARKET

09.00
Keynote: Implementing strategies to consolidate market presence in Asia’s emerging vaccine markets
Mr Michel Vounatsos at World Vaccine Congress Asia 2012

Mr Michel Vounatsos

With nearly 20 years of experience in the healthcare industry, Michel Vounatsos brings to MSD China the vast knowledge and expertise we need to drive us to new levels of success. Mr. Vounatsos has had extensive business experience across the...

more..

  • Aligning priorities along key growth drivers to capitalise on emerging opportunities
  • Utilising regional advantages  to strengthen vaccine development and production capabilities
  • Leveraging on regional networks to maintain preparedness and achieve first mover advantages
     

09.20
Identifying potential partnerships and executing them effectively across different Asian markets
Mr Labeeb Abboud at World Vaccine Congress Asia 2012

Mr Labeeb Abboud

Labeeb M. Abboud is Senior Vice President and General Counsel of the International AIDS Vaccine Initiative, a non-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use...

more..

  • IAVI’s successful partnerships across India, China and Japan
  • Overcoming challenges in public-private-partnerships
  • Identifying the right angle to partner with industry or research institutes

 

09.40
Driving more effective and profitable immunisation strategies through public-private-partnerships
Mr Monir Islam at World Vaccine Congress Asia 2012

Mr Monir Islam

Dr Quazi Monirul Islam, is the Director of the Department of Family Health and Research, World Health Organization, South East Asia Regional Office, New Delhi, India. Dr Islam is a public health specialist qualified from Dhaka...

more..

  • Achieving profitability and market leadership through effective partnering
  • Exceeding immunisation targets by leveraging private sector partners
  • Guaranteeing ROI for all stakeholders by employing effective partnering models

 

10.00
Morning refreshments, exhibition viewing, academic poster showcase & on-floor demo session

ALLIANCES AND PARTNERSHIPS AS THE FUTURE OF THE ASIAN VACCINE MARKET

11.00
Successful partnering in Asia and how to ensure a good fit
Mr Stanley Chang at World Vaccine Congress Asia 2012

Mr Stanley Chang

Previous Medical Positions 1996~2000 Chairman, Faculty of Medicine, Tzu-Chi University 1993~1996 Research Urologist, UCL Middlesex Hospital, London 1992~2000 Associate Professor in Urology 1989~1991 Chairman, Department of Urology, Tzu-Chi General...

more..

11.20
Plant-based VLPs: sowing innovative seeds in the Asian vaccine market
Frederic Ors at World Vaccine Congress Asia 2012

Frederic Ors

Mr. Ors has more than ten years of experience in Licensing, Intellectual Property and business development in biotechnology. He joined Medicago in 2001 and oversees Business Development activities. He is also responsible for securing Medicago's...

more..

  • Opportunities for novel technologies in Asia: perspective of a Biotech company
  • Introduction on Medicago technologies and potential to improve vaccine development and access in Asia
  • Example of global partnering with Asian player: Medicago and Mitsubishi Pharma deal

 

11.40
How can innovations and technologies help India reach universal immunization coverage?
Natela Menabde at World Vaccine Congress Asia 2012

Natela Menabde

Dr Nata Menabde has a solid public health academic background and 28 years of experience as a health professional, during which she has built an extensive track record in public health and health systems at country and international levels. As a...

more..

  • Successes and challenges
  • Striking a balance in public-private-partnerships

 

12.00
Networking luncheon, exhibition viewing, academic poster showcase & on-floor demo session

SUCCESSFUL VACCINE PROJECTS IN ASIA

14.00
Capitalising on comparative advantages during partnering between western and Asian vaccine leaders
Mr Pierre Catignol at World Vaccine Congress Asia 2012

  • Exploiting key advantages between both sides and combining these into a coherent strategy
  • Defining effective strategies to identify potential partners
  • Implementing cross continental partnerships to achieve advantages globally
     

14.30
Ensuring successful vaccine projects in international collaboration
Kapil Maithal at World Vaccine Congress Asia 2012

Kapil Maithal

Dr. Kapil Maithal is Director-Program Management at International AIDS Vaccine Initiative, a non-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the...

more..

15.00
Singapore’s childhood immunization programme: success and challenges

  • The evolution of the national childhood immunization programme from diphtheria over tuberculosis to mumps
  • Evaluating the success in immunization coverage, disease incidence and immune status
  • Challenges including the introduction of other vaccines

 

    15.30
    Afternoon refreshments, exhibition visit, academic poster showcase & on-floor demo session

    INNOVATIVE INTERNATIONAL VACCINE DEVELOPMENTS

    16.00
    Decevax: Platform technology for Immunotherapy of Cancer
    Shakti Upadhyay at World Vaccine Congress Asia 2012

    Shakti Upadhyay

    Dr. Shakti Upadhyay’s experience spans more than 30 years of research in diverse fields such as cell biology, reproductive biology, endocrinology, embryology and immunopharmacology. He holds Ph.D. from University of Paris, France (1977). He worked...

    more..

    16.20
    Innovative International Vaccine Developments
    Jan Ter Meulen at World Vaccine Congress Asia 2012

    Jan Ter Meulen

    Dr. Jan ter Meulen joined Merck Research Laboratories in 2008 and is responsible for the leadership of all laboratory research on vaccine discovery programs. From 2003 to 2007 he held various positions at Crucell Holland bv, where he pursued the...

    more..

    Leading global and Asian biotechs, pharmas and research institutes will showcase their latest vaccine developments looking for potential partners globally and across Asia. Potential partnerships run from research and development to licensing and collaboration in vaccine commercialization.

    16.40
    Molecular Painting: a novel method for biomembrane surface modification with wide-reaching applications
    John Dangerfield at World Vaccine Congress Asia 2012

    17.00
    Chairman’s closing remarks
    17.05
    End of conference day two

    Register for World Vaccine Congress Asia 2012 ›

    Get the World Vaccine Congress Asia 2012 brochure ›

    Back to top ›

    last modified: 24 May '12

    Developing effective production strategies for multi-vaccine manufacturing in Asia

    • Evaluating specific challenges associated with manufacturing different vaccines
    • Developing robust approaches to fully utilise production facility
    • Exploring the different strategies available for ensuring quality control and regulatory compliance

    Growing vaccine pipeline value through effective partnering and investment strategies in Asia

    Asia contains a wide variety of vaccine markets, each with different advantages due to cultural, economic and geographic differences. Identifying the right partners to develop vaccines from initial R&D through trials to commercialization requires a strategic and well defined approach.
    This workshop will assist participants in understanding how to approach the Asian market for external research and development and how to successfully build a pipeline through strategic partnerships.

    Transitioning existing biologics processes into single use technology platform to enable global deployment

    • Factors to consider before implementation: performance equivalency, quality, logistics and business needs
    • Evaluating which single-use equipment to utilize, considering cost and which stage should be implemented first
    • Examining before and after implementation for optimum efficiency

    Optimising cost-effective Japanese Encephalitis (JE) vaccine development in Asia

    • Evaluating current development on inactivated and live molecular JE vaccine for the global population
    • Tapping on lessons learnt from producing the vaccine in Asia
    • Case study: Assessing the long term immunity of live attenuated Japanese encephalitis chimeric virus vaccine

    Innovative vaccine design: Important chemistry, manufacturing and controls (CMC) issues in adjuvant development

    • Uncovering new concepts and knowledge about innovative vaccine design; innate immunity and beyond
    • Tapping on advanced technologies of immune-manipulation and delivery system in Japan
    • Overcoming regulatory hurdles and harnessing the potential for adjuvants in Japan; key factors for very safe and efficacious vaccines

    Innovative International Vaccine Developments

    Leading global and Asian biotechs, pharmas and research institutes will showcase their latest vaccine developments looking for potential partners globally and across Asia. Potential partnerships run from research and development to licensing and collaboration in vaccine commercialization.

    sponsor World Vaccine Congress Asia 2012 ›

    Sponsors
    Platinum sponsor
    GE Healthcare at World Vaccine Congress Asia 2012
    Gold Sponsor
    Merck Millipore at World Vaccine Congress Asia 2012
    Silver Sponsor
    Medicago Inc at World Vaccine Congress Asia 2012
    Bronze sponsor
    Finesse Solutions, LLC at World Vaccine Congress Asia 2012
    Bronze Sponsor
    ViroClinics Biosciences B.V. at World Vaccine Congress Asia 2012
    Innovative showcase sponsor
    Bavarian Nordic A/S at World Vaccine Congress Asia 2012
    Innovative biotech showcase sponsor
    Immune Targeting Systems (ITS) Ltd at World Vaccine Congress Asia 2012

    sponsors list ›